The Logistics of Clinical Trial Kits: Preventing Site Errors

Where Clinical Data Is Actually Lost

In a well-designed clinical trial, the analytical plan, the bioanalytical methods, the statistical model, and the regulatory strategy all receive careful attention. What often receives less attention is the physical act of collecting, labelling, processing, and shipping the biological samples that all of that methodology depends on. Yet errors at the sample collection stage produce data that is unusable, and unusable samples translate directly into missing data points that can weaken the statistical confidence of the study or trigger protocol deviation reports that complicate the regulatory submission.

The most common sources of clinical sample error are not wilful or random. They are predictable failures driven by poorly designed clinical trial kits, inadequate site training, or logistical processes that are too complex for a busy nurse or clinical site coordinator to execute reliably under time pressure.

The Most Common Clinical Sample Errors and Their Causes

Error Type	Common Cause	Consequence	Prevention Strategy
Sample mislabelling	Manual label application; ambiguous label format; no barcode	Sample cannot be attributed to patient or timepoint; data lost	Pre-printed barcode labels; one label per tube design; kit personalisation to patient ID
Incorrect tube type	Multiple tube types in kit without clear differentiation	Anticoagulant incompatibility; sample unusable	Colour-coded tubes with unambiguous visual hierarchy; single visit type per kit
Wrong processing procedure	Complex centrifugation steps without clear instruction	Incorrect matrix; haemolysis; cells not separated	Laminated step-by-step processing card; pictorial instructions; pre-centrifuged tube option
Missed timepoint	No alert for critical PK sample windows	Sparse PK profile; impaired PK modelling	Electronic alert system or timed label cards; site coordinator checklist
Incorrect storage or temperature excursion	Samples stored at room temperature pending shipment	Analyte degradation; stability failure	Cool packs integrated into kit; clear storage instruction on every tube
Shipping documentation error	IATA documentation incomplete or missing	Sample held in customs; delayed or refused delivery	Pre-completed customs documentation; clinical supply partner coordinates shipping

Principles of Good Clinical Trial Kit Design

Design for the Least Experienced User

A clinical trial kit will be used by nurses and site coordinators at dozens of different sites, with different training backgrounds, different levels of familiarity with clinical research, and different workloads on the day of the visit. The kit design must be idiot-proof in the literal sense: it should make the correct action the easiest action, and the incorrect action difficult or impossible to take by accident.

Minimise the Number of Decisions the Site Must Make

Every decision that the site is required to make at the point of sample collection is an opportunity for an error. Pre-labelled tubes eliminate the labelling decision. Visit-specific kits that contain only the tubes needed for that visit eliminate the tube selection decision. Pre-positioned cool packs that are activated automatically when the kit is opened eliminate the storage decision. Good kit design removes decisions, not adds instructions about how to make them.

Test the Kit in a Simulated Use Environment

Before a clinical trial kit goes to sites, it should be tested by people who represent the intended users but who were not involved in designing it. Simulated use testing often reveals ambiguities and failure modes that are invisible to the design team but obvious to a nurse encountering the kit for the first time. This investment at the design stage prevents protocol deviations at the collection stage.

Patient Kit Services at Ardena

Ardena’s clinical supply and bioanalytical teams at Assen provide end-to-end patient kit services for clinical trials, from kit design through to sample receipt and processing. Kits are assembled and quality-checked at Assen, with pre-labelled tubes, visit-specific configurations, and integrated cold chain components as standard.

Ardena coordinates clinical sample logistics including temperature-controlled shipping from investigator sites across Europe and beyond, customs documentation for international shipments, and chain-of-custody tracking from site to laboratory. The same team that designs the kit is responsible for receiving and processing the samples, creating a closed-loop system where kit design decisions are informed by direct experience of what goes wrong in transit and at the bench.

The Science of Solubility: Particle Size Reduction Techniques

Why Particle Size Matters for Oral Drug Absorption

The Noyes-Whitney equation, a cornerstone of pharmaceutical dissolution science, tells us that the rate of dissolution of a solid is proportional to its surface area. Reducing the particle size of a poorly soluble API increases the surface area exposed to the dissolution medium, which increases the dissolution rate, and for molecules where dissolution is the rate-limiting step in absorption, this translates directly into improved oral bioavailability.

Particle size reduction is one of the most widely used and well-understood strategies for addressing solubility challenges in oral drug products. It does not require a change in solid form, a new polymer system, or a significant change in formulation architecture. For many BCS Class II molecules, it can provide all the bioavailability improvement needed with a relatively straightforward manufacturing process.

The Three Primary Particle Size Reduction Technologies

Jet Milling (Micronisation)

Jet milling uses high-pressure streams of gas, typically nitrogen or compressed air, to accelerate drug particles to high velocities and drive them into collisions with each other and with the walls of the milling chamber. The result is a dry, crystalline powder with a particle size typically in the range of 1 to 20 micrometres.

Jet milling is well-established, scalable, and produces a product that is relatively easy to characterise and handle. It is the particle size reduction method of choice for potent compounds where containment during processing is critical, because the dry milling process can be conducted in a closed, contained system. However, it has limitations: it cannot reliably produce particles below about 1 micrometre, and it can cause polymorphic conversion or surface amorphisation if the API is thermally or mechanically sensitive.

Wet Milling (Media Milling)

Wet milling suspends the API in an aqueous medium with appropriate stabilisers and uses grinding media, typically ceramic or polymeric beads, to reduce particle size through attrition and impact. Wet milling can achieve smaller and more uniform particle sizes than jet milling, typically in the 200 nanometre to 5 micrometre range.

The stabiliser system used in wet milling is critical. The stabiliser prevents particle aggregation during milling and in the final suspension. Common stabilisers include HPMC, poloxamer, and polysorbate 20 or 80. The choice of stabiliser affects not only the physical stability of the suspension but also the dissolution performance of the final product.

Bottom-Up Precipitation (Nanosuspension by Anti-Solvent)

Rather than breaking down larger particles, bottom-up approaches start with a molecular solution of the API and induce controlled precipitation of nanoparticles by mixing with an anti-solvent. The particle size and distribution are controlled by mixing conditions, temperature, and the stabiliser system. Bottom-up approaches can achieve very small and uniform particle sizes but are more complex to scale and control than top-down methods.

Technology Comparison for Particle Size Reduction

Factor	Jet Milling	Wet Milling	Bottom-Up Precipitation
Achievable particle size	1-20 micrometres	200 nm – 5 micrometres	50-500 nm
Solid state of product	Crystalline (risk of surface amorphisation)	Crystalline	Variable; can be amorphous
Process type	Dry	Wet suspension	Wet suspension
Containment for HPAPIs	Excellent; closed system	Moderate	Moderate
Scale-up complexity	Established, well-understood	Established for pharmaceutical use	More complex; sensitive to mixing conditions
Regulatory precedent	Extensive	Extensive (Rapamune, Tricor precedents)	Growing
Key limitation	Cannot achieve sub-micron reliably	Stabiliser selection critical	Scale-up control challenging

Particle size ranges and characteristics above are representative of typical pharmaceutical processes and are drawn from published literature. Programme-specific outcomes depend on API properties and process conditions.

Choosing the Right Approach for Your Molecule

The selection of particle size reduction technology depends on several factors: the target particle size needed to achieve the desired dissolution enhancement, the physical and chemical stability of the API under milling conditions, the intended final dosage form, and the manufacturing scale at which the process will ultimately run.

For potent or cytotoxic compounds, the ability to conduct the entire process in a contained, dry environment makes jet milling the preferred first choice. For molecules where sub-micron particles are needed to achieve meaningful bioavailability improvement, wet milling or a combined approach may be required. A feasibility study comparing dissolution performance across particle size ranges is the most reliable way to establish the target specification and select the technology.

Ardena’s Particle Size Reduction Capabilities

Ardena’s Pamplona (Idifarma) facility has dedicated particle size reduction capabilities including jet milling for API micronisation, with containment suitable for high-potency compounds. The analytical teams at Ardena use laser diffraction and dynamic light scattering for particle size characterisation and dissolution testing in biorelevant media to assess the in vitro performance impact of particle size reduction.

Particle size reduction studies at Ardena are conducted alongside the broader formulation programme, ensuring that decisions about milling approach and target particle size are informed by dissolution data and downstream processability assessment rather than treated as a standalone analytical exercise.

Bridging Studies: Changing Formulations Mid-Clinical Trial

Formulation Change Is Inevitable

It is the rare pharmaceutical development programme that reaches Phase III with exactly the same formulation that entered Phase I. Scale-up changes, stability-driven modifications, bioavailability improvements, and the practical realities of manufacturing optimisation all result in formulation differences between the early clinical and the intended commercial product.

This is not a problem in itself. Regulators understand that development involves iteration. What they need to be confident of is that the clinical data generated with earlier formulations is still relevant to the product being developed, and that any changes have been characterised, controlled, and disclosed appropriately. Bridging studies are the mechanism for providing that confidence.

When a Bridging Study Is Required

The requirement for a bridging study depends on the nature and magnitude of the formulation change, and the stage of development at which it occurs. FDA’s guidance on INDs and EMA’s guidance on clinical trial authorisations both address formulation changes, though the specific triggers and requirements differ between jurisdictions.

Change Type	Likely Bridging Requirement	Bridging Approach
Minor composition change (same formulation concept, adjusted ratio)	Comparative dissolution in multiple pH media	In vitro dissolution comparison; statistical evaluation
Bioavailability-enhancing technology change (e.g. crystalline to ASD)	In vivo pharmacokinetic bridging study	Crossover PK study in healthy volunteers or patients
Dosage form change (e.g. capsule to tablet)	Comparative dissolution; potentially in vivo PK	In vitro first; in vivo if dissolution differences identified
Manufacturing site or scale change	Comparative analytical data; potentially dissolution	Batch analysis comparison; process validation data
Excipient change (novel excipient or significant level change)	Regulatory assessment; potentially safety bridging	Toxicology assessment of new excipient if required

In Vitro Dissolution as a Bridging Tool

For many formulation changes where the mechanism of absorption is not fundamentally altered, comparative dissolution testing in multiple pH media is the first-line bridging tool. Dissolution testing at pH 1.2, 4.5, and 6.8 captures the range of conditions encountered in the gastrointestinal tract and provides evidence that the modified formulation will deliver the drug at a comparable rate and extent.

The statistical approach to comparing dissolution profiles, using the f2 similarity factor or more sophisticated modelling approaches, is addressed in FDA’s dissolution guidance for industry and the EMA’s guideline on dissolution. An f2 value of 50 or greater indicates similarity for most formulation types, though this criterion does not apply to highly variable drugs or drugs with narrow therapeutic windows.

In Vivo PK Bridging Studies

When an in vitro approach is not sufficient to bridge a formulation change, an in vivo pharmacokinetic study in human subjects is required. The design of a PK bridging study depends on the objectives: for a change that may affect rate of absorption but not extent, a crossover study in healthy volunteers measuring Cmax and AUC is typically the most efficient approach. For changes where the effect on bioavailability is expected to be small, a two-period crossover with a 90% confidence interval approach is standard.

Planning PK bridging studies as part of the CMC development strategy, rather than as a reactive response to a regulatory question, avoids the scenario of needing to design and execute a clinical study under time pressure at a critical programme milestone.

Practical Considerations for Formulation Change Management

Document the Scientific Rationale

Every formulation change should be accompanied by a written scientific rationale that explains why the change was made, what data supported the decision, and how the bridging approach was selected. This documentation is both good practice and a regulatory requirement for programmes operating under an active IND or CTA.

Engage Regulators Early

For changes that are likely to require in vivo bridging, early engagement with the relevant regulatory agency, through a Type B meeting request to the FDA or a scientific advice procedure at the EMA, can clarify the bridging expectations before the study is designed. This avoids the risk of executing a study that does not satisfy the agency’s requirements.

Consider the Phase of Development

A formulation change at Phase I is far easier to manage than the same change at Phase III. The earlier a formulation is locked, or a deliberate development path to the intended commercial formulation is established, the less bridging work will ultimately be required.

How Ardena Supports Formulation Change Management

Ardena’s integrated CMC teams manage formulation change programmes across its development and analytical sites. The analytical teams in Ghent and Assen develop and execute comparative dissolution studies and provide the bioanalytical support for in vivo PK bridging studies. The regulatory team advises on jurisdiction-specific requirements and can prepare the CMC change documentation needed for IND amendments or CTA updates.

Impact of Solid Form on Intellectual Property (IP)

The Commercial Life of a Drug Molecule

A new drug’s commercial life is bounded by its patent estate. The composition of matter patent, which covers the chemical structure of the active ingredient, is typically the most valuable piece of IP and is usually filed at or near the time of initial synthesis. By the time a drug reaches the market, after a development programme that commonly takes ten to fifteen years, much of the composition of matter patent life has already been consumed.

This is where solid form IP becomes commercially significant. A patent covering a novel crystal polymorph, a pharmaceutically beneficial salt form, or a co-crystal with advantages over existing forms can be filed and prosecuted independently of the composition of matter patent, and can provide exclusivity that extends well beyond it.

What Can Be Patented in Solid Form Work

Novel Polymorphs

A new crystalline form of a known API may be patentable if it is novel, non-obvious, and has utility. Patentability is typically supported by demonstrating that the polymorph has advantages over previously known forms, such as improved chemical stability, more favourable hygroscopicity, better manufacturability, or improved dissolution performance. An XRPD characterisation establishing the uniqueness of the form is a standard element of a polymorph patent application.

Salt Forms

A novel pharmaceutical salt is patentable if it is not described in the prior art and has demonstrated physicochemical advantages. The patent should describe the process for preparing the salt, its analytical characterisation, and the evidence for its advantages. Salt patents have a long history in pharmaceutical IP, and the prior art landscape for common APIs is often dense, making thorough prior art searching an important early step.

Co-Crystals

The patentability of pharmaceutical co-crystals has been established through a series of patent office decisions and court cases in major jurisdictions over the past fifteen years. A novel co-crystal with demonstrable advantages, supported by characterisation data and evidence of the co-crystal nature of the material, is a patentable entity in most jurisdictions. The regulatory status of the coformer, whether it is a GRAS substance or an approved excipient, is relevant to patentability arguments in some cases.

IP Strategy Considerations by Solid Form Type

Form Type	IP Opportunity	Key Evidence Required	Timing Consideration
Polymorph	New crystal form with demonstrated stability or performance advantage	XRPD characterisation; stability comparison to other known forms	File before public disclosure; prior art search essential
Pharmaceutical salt	Novel counterion combination with physicochemical advantages	Characterisation of salt; solubility/stability comparison to free form	Screen broadly; file on most promising forms
Co-crystal	Non-ionic multicomponent crystal with measurable advantage	Crystal structure confirmation; coformer identification; comparative data	Growing patent landscape; freedom to operate analysis important
Amorphous dispersion	Novel polymer-drug combination or process for preparation	Characterisation of dispersion; stability and dissolution data	Process patents may offer longer-term protection than form patents

The Risk of Not Screening Thoroughly

The IP risk of incomplete solid state screening runs in both directions. If your development team works with the first crystal form synthesised and a competitor later patents a more stable polymorph, you may face freedom-to-operate issues when you move to commercial manufacturing. Conversely, if you do not identify and protect novel forms early, you risk a competitor doing so and establishing a blocking position on what you might eventually want to use as your commercial form.

Thorough solid state screening, conducted systematically with a combined scientific and IP lens, is the most effective way to both secure your own IP position and establish freedom to operate in your intended commercial form.

How Ardena Supports Solid Form IP Strategy

Ardena’s solid state research team in Ghent conducts polymorph, salt, and co-crystal screening programmes designed to generate data of the quality and scope needed to support patent applications. The team is experienced in structuring screening work to systematically explore the solid form landscape and in generating the characterisation data, including XRPD, DSC, TGA, and comparative physicochemical data, that patent attorneys need to prosecute a strong application.

Ardena works with clients and their patent counsel to ensure that the timing of screening work, the documentation of findings, and the structure of the characterisation data package all support the IP strategy alongside the development programme.

Build Your Solid Form IP Strategy with Ardena

If you want to understand the IP landscape for your molecule’s solid forms, or design a screening programme that generates patentable data, our team in Ghent is ready to discuss your programme.

X-Ray Powder Diffraction (XRPD) in Drug Development

Why Solid Form Characterisation Starts with XRPD

X-ray powder diffraction (XRPD) is the most widely used technique for characterising the crystalline structure of pharmaceutical solids. Every crystalline form of a drug substance produces a unique diffraction pattern, a fingerprint determined by the arrangement of molecules in the crystal lattice. This fingerprint allows scientists to identify which polymorph, salt, hydrate, or solvate is present in a sample, and to detect the presence of multiple forms in a mixture.

For drug development, this capability is critical at almost every stage. In pre-formulation, XRPD maps the solid state landscape of the API. During formulation development, it monitors whether an amorphous dispersion has begun to recrystallise. In GMP manufacturing, it confirms batch-to-batch consistency of the crystalline form. And in regulatory submissions, the XRPD pattern of the intended commercial form is a required element of the Module 3 CTD.

How XRPD Works

When a beam of X-rays strikes a crystalline material, the periodic arrangement of atoms in the lattice causes the X-rays to diffract at specific angles. The resulting diffraction pattern, a series of peaks at characteristic 2-theta angles with characteristic relative intensities, is determined by the geometry of the crystal lattice and the identity of the atoms within it. Different polymorphs of the same molecule have different lattice geometries and therefore produce different XRPD patterns.

Variable temperature XRPD allows the solid state behaviour of a compound to be monitored in real time as it is heated or cooled, revealing polymorphic transitions, melting events, and recrystallisation phenomena that cannot be captured by measurements at a single temperature.

XRPD Applications Across the Drug Development Lifecycle

Development Stage	XRPD Application	What It Answers
Pre-formulation	Polymorph screening characterisation	Which crystalline forms exist? Which is the thermodynamic stable form?
Salt and co-crystal screening	Form identification and confirmation	Is the screen hit a salt, co-crystal, or solvate? Is it a new crystalline form?
ASD development	Amorphous state confirmation and recrystallisation monitoring	Is the API fully amorphous after processing? Has any recrystallisation occurred?
Formulation development	Drug-excipient compatibility	Have any crystalline interactions or form conversions occurred in the blend?
GMP manufacturing	In-process and release testing	Does the batch contain the correct crystalline form? Are there unexpected peaks?
Stability testing	Physical stability monitoring	Has the solid form changed under ICH storage conditions?
Regulatory submission	Reference pattern for Module 3	What is the defining XRPD fingerprint of the approved solid form?

XRPD vs. Other Solid State Characterisation Techniques

XRPD is the primary tool for solid form identification, but it works best alongside complementary techniques. Differential scanning calorimetry (DSC) provides thermal event data, including melting points, polymorphic transitions, and glass transition temperatures, that complement the structural information from XRPD. Thermogravimetric analysis (TGA) measures mass loss as a function of temperature, confirming solvate and hydrate stoichiometry. Raman spectroscopy and solid-state NMR provide molecular-level information about bonding and environment that can resolve ambiguities in XRPD data.

A complete solid state characterisation programme uses all of these techniques in combination, with XRPD as the reference method for form identification and batch control.

Regulatory Expectations for XRPD Data

The ICH Q6A guideline on specifications for new drug substances requires that the solid state form of the drug substance is defined and included in the specification when it affects drug performance or manufacturability. The reference XRPD pattern of the intended commercial form must be included in Module 3.2.S of the CTD, and the specification must include a test for solid form identity using XRPD or an equivalent technique.

For amorphous drug substances and amorphous solid dispersions, the regulatory expectation is that the absence of crystallinity is demonstrated by XRPD, and that stability studies monitor for crystalline conversion over the proposed shelf life.

XRPD Capability at Ardena Ghent

Ardena’s solid state research facility in Ghent operates transmission and reflection XRPD instruments capable of routine form identification, high-sensitivity amorphous detection, and variable temperature measurements. The analytical team has extensive experience interpreting XRPD data in the context of pharmaceutical development, including for complex mixtures, amorphous materials, and novel salt and co-crystal forms.

XRPD data generated in Ghent is directly connected to the development programme, ensuring that form-related findings are interpreted in context and feed immediately into formulation and regulatory strategy decisions.

Strategic CMC Advice: Bridging Preclinical to Phase II

CMC Strategy Is Not a Static Document

There is a common misconception in early drug development that CMC strategy means writing a dossier. It does not. CMC strategy means making deliberate decisions, at every stage of development, about which data to generate, which manufacturing processes to lock, and how to position the product for the regulatory interactions that lie ahead.

The CMC strategy appropriate for an IND or Phase I IMPD filing is structurally different from the strategy needed to support a Phase II submission, and different again from what an NDA or MAA will require. A development team that treats its CMC work as a series of discrete filing exercises, rather than as a continuously evolving strategy, typically creates avoidable work and avoidable risk at each transition.

CMC Requirements at Each Development Stage

Development Stage	Regulatory Filing	CMC Data Expectations	Key Decisions
Preclinical / IND-enabling	IND (US) / IMPD (EU)	Fit-for-purpose; sufficient to support safety of first dose. Process need not be final.	Solid form selection; initial specification setting; stability to cover trial duration
Phase I	IND amendment / IMPD update	Characterisation of development batches; preliminary stability. Process may still evolve.	Scale-up direction; control strategy development; method development roadmap
Phase II	IND amendment / clinical trial authorisation update	More complete characterisation; comparative dissolution if formulation changed; updated stability	Formulation and process lock or defined change control; bridging data if formulation changed
Phase III / NDA/MAA	NDA / MAA Module 3	Full ICH Q6A specification; validated methods; 12 months real-time stability; process validation	Specification finalisation; scale-up and validation; regulatory starting material justification

The Formulation Lock Decision

One of the most consequential CMC decisions in early development is when to lock the formulation. A formulation change between Phase I and Phase II is manageable with appropriate bridging data. A formulation change between Phase II and Phase III is significantly more costly and time-consuming, requiring bioequivalence or pharmacokinetic bridging data to justify the change to regulators.

The FDA’s guidance on comparability protocols and the EMA’s guidance on changes to approved products provide frameworks for managing post-approval changes, but the optimal strategy is to make the major formulation decisions as early as the data allows, so that the Phase II formulation is as close as possible to the one that will go into Phase III and registration.

Regulatory Starting Materials and Their Long-Term Impact

The designation of regulatory starting materials (RSMs) for the drug substance synthesis has long-term implications for the regulatory dossier and for commercial supply chain flexibility. Designating a starting material too early in the synthetic route creates a large regulatory footprint that is difficult to modify later. Designating it too late, at a complex intermediate, may not be accepted by regulators. Getting the RSM designation right at the IND stage, with a view to how the synthetic route will evolve through development and into commercial manufacture, is a decision that benefits from early input from an experienced CMC regulatory team.

Managing Formulation Changes with Bridging Data

It is unusual for the Phase I formulation to be identical to the commercial formulation. Scale-up changes, manufacturing process improvements, and changes driven by stability or bioavailability data all occur during development. Each change creates a potential regulatory question about whether the clinical data generated with the earlier formulation is still representative of the product being developed.

Bridging studies, whether dissolution comparisons, pharmacokinetic crossover studies, or formal bioequivalence studies, provide the evidence base for justifying formulation changes to health authorities. Planning for these studies as part of the CMC strategy, rather than retrospectively, avoids last-minute surprises at the Phase II or III transition.

How Ardena Builds CMC Strategy into Development Programmes

Ardena’s CMC regulatory advisors work alongside the formulation and analytical teams throughout development programmes, not just at filing milestones. This means that the CMC strategy is reviewed and updated as the science evolves, and that decisions with long-term regulatory implications, such as solid form selection, RSM designation, and specification setting, are made with full visibility of their downstream consequences.

For programmes approaching the Phase I to Phase II transition, Ardena can conduct a CMC gap analysis against the requirements for the next regulatory filing and identify the studies needed to close those gaps efficiently.

Amorphous vs. Crystalline: Managing Stability Risks

The Stability Trade-Off at the Heart of ASD Formulation

The physicochemical advantage of an amorphous solid dispersion is real and well-documented. By eliminating the crystal lattice energy barrier, amorphous forms dissolve faster and achieve higher apparent solubility in biological fluids. For BCS Class II molecules with poor oral bioavailability, this translates directly into better clinical performance.

But amorphous forms pay for that advantage with thermodynamic instability. An amorphous solid is at a higher energy state than its crystalline counterpart. Given sufficient molecular mobility, the amorphous drug will tend to return to the crystalline state, losing the solubility advantage that made the formulation worthwhile. Managing this tendency, across the manufacturing process, the packaging, and the intended shelf life, is the central stability challenge of ASD development.

The Physics of Recrystallisation

Glass Transition Temperature (Tg)

The glass transition temperature is the single most important physical parameter for understanding the stability of an amorphous solid. Below the Tg, molecular mobility in the amorphous matrix is very low, and recrystallisation is kinetically inhibited. Above the Tg, mobility increases substantially, and the rate of crystallisation increases rapidly. For practical storage stability, the Tg of the amorphous drug or ASD should be significantly above the intended storage temperature. A rule of thumb used in the field is that the Tg should be at least 50 degrees Celsius above the storage temperature, though this is a guideline rather than a regulatory requirement.

The Effect of Moisture

Water acts as a plasticiser for amorphous solids, reducing the Tg and increasing molecular mobility. An amorphous drug that is stable under dry conditions may crystallise rapidly when exposed to elevated humidity. This makes moisture control during manufacturing and packaging critical. It also means that ICH stability studies at 75% relative humidity are a particularly challenging condition for amorphous formulations and an important test of the robustness of the stabilisation strategy.

Drug-Polymer Miscibility

In an amorphous solid dispersion, the drug must remain miscible with the polymer matrix throughout its shelf life. Phase separation, where the drug migrates out of the polymer matrix into drug-rich domains, accelerates recrystallisation. Drug-polymer miscibility is assessed using techniques including modulated DSC, solid-state NMR, and computational solubility parameter calculations during formulation development.

Stability Risk Assessment Framework

Risk Factor	Low Risk Indicator	High Risk Indicator	Mitigation
Tg of ASD	Greater than 80 degrees C at ICH storage conditions	Below 60 degrees C	Increase polymer content; use higher-Tg polymer
Moisture sensitivity	Tg reduction less than 10 degrees C at 75% RH	Tg reduction greater than 20 degrees C	Moisture-barrier packaging; desiccant; enteric coating
Drug-polymer miscibility	Single Tg observed; no phase separation by DSC	Two Tg events or crystalline peaks in XRPD	Reformulate with more compatible polymer
Recrystallisation tendency	No XRPD peaks after 6 months at 40 degrees C/75% RH	XRPD peaks within 1-3 months	Increase polymer ratio; add crystallisation inhibitor
Drug loading	Below 30% w/w	Above 50% w/w	Evaluate lower drug loading; consider alternative polymer

The thresholds above represent general guidance based on published ASD development literature and are not regulatory requirements. Programme-specific assessment is always required.

Analytical Tools for Monitoring Amorphous Stability

A stability monitoring programme for an ASD must be able to detect early-stage recrystallisation before it becomes analytically visible by standard release methods. The analytical toolkit for amorphous stability monitoring includes XRPD for detecting crystalline conversion, modulated DSC for measuring Tg and detecting phase separation, and dissolution testing using biorelevant media to capture changes in in vitro performance. Raman spectroscopy and solid-state NMR offer additional sensitivity for detecting early molecular-level changes.

How Ardena Manages ASD Stability

Ardena’s formulation teams at Somerset and Pamplona design ASD stability programmes that integrate physical stability monitoring with dissolution performance assessment from the earliest development batches. Stability studies are structured to generate data that supports regulatory filings under ICH Q1A(R2), with additional stress conditions designed to probe the specific failure modes relevant to the formulation.

The solid state research team in Ghent provides the advanced characterisation capabilities needed to understand drug-polymer interactions and phase behaviour, feeding data into the formulation decisions made at Somerset and Pamplona in a coordinated way.

Preparing Module 3 of the CTD: A Practical Guide

Why CMC Filings Slow Programmes Down

The Common Technical Document (CTD) format is used for regulatory submissions across the major pharmaceutical markets. Module 3, the Quality section, contains the chemistry, manufacturing, and controls data for both the drug substance and the drug product. It is the section that drug developers frequently underestimate in terms of the time and rigour required to prepare it well.

For IND submissions in the United States, FDA first-cycle CMC deficiency letters are common. For IMPD submissions in Europe, national competent authorities regularly request additional information before granting a clinical trial authorisation. In both cases, the delay between submission and the first patient dosed is extended, often by months, by issues that could have been addressed during the writing process with appropriate regulatory expertise.

What Module 3 Contains

Module 3 Section	Content	Key Regulatory Expectation
3.2.S — Drug Substance	Nomenclature, structure, synthesis, characterisation, standards, container closure	Complete route of synthesis with controls at each step; solid form defined and controlled
3.2.S.3 — Characterisation	Structural confirmation, impurity profile	Relevant impurities identified, qualified, and controlled per ICH Q3A
3.2.S.4 — Control of Drug Substance	Specification, analytical procedures, validation	Methods suitable for their purpose; specifications justified
3.2.S.7 — Stability	Stability data supporting retest period or shelf life	ICH Q1 conditions; data from primary batches
3.2.P — Drug Product	Description, formulation, manufacture, characterisation, standards	Manufacturing process described with controls; critical steps identified
3.2.P.5 — Control of Drug Product	Release specification and methods	Dissolution method development and validation documented
3.2.P.8 — Stability	Drug product stability supporting proposed shelf life	Photostability per ICH Q1B; representative commercial-scale batches for NDA/MAA

The Five Most Common Module 3 Mistakes

1. Insufficient Specification Justification

A specification is only as strong as the justification behind it. Regulators expect specifications to be set based on a combination of process capability data, safety-relevant impurity thresholds, and clinical batch data. Specifications that appear to have been set arbitrarily, or that are simply taken from a pharmacopoeial monograph without justification specific to the molecule, are a routine source of questions.

2. Incomplete Impurity Qualification

ICH Q3A requires that impurities in the drug substance above threshold levels are identified and, where necessary, qualified by toxicological assessment. Submissions that list impurities without identifying them, or that rely on qualification from structurally unrelated compounds, frequently receive deficiency letters asking for additional justification. This is an area where early engagement with an experienced regulatory team is particularly valuable.

3. Poorly Described Manufacturing Processes

The manufacturing process narrative in Module 3 must describe the process in sufficient detail for a regulator to understand the critical steps and the controls applied at each stage. Descriptions that are too high-level leave regulators unable to assess the adequacy of process control, while descriptions that are too detailed create problems when the process changes. Calibrating the level of detail appropriately requires regulatory writing experience.

4. Stability Data That Does Not Support the Proposed Shelf Life

For a Phase I filing, the data required to support the proposed retest period or shelf life may be limited, but it must be sufficient to cover the duration of the intended clinical trial. ICH Q1A(R2) sets out the minimum stability data requirements. Submissions that propose a shelf life not supported by data from the appropriate ICH storage conditions, or that use accelerated data where real-time data is required, are a predictable source of delay.

5. Inconsistencies Between Sections

Module 3 is assembled from data generated by multiple teams over an extended period. Inconsistencies between sections, such as a batch size in the manufacturing description that does not match the batch numbers in the stability section, or an analytical method in section P.5 that differs from the method used to generate the data in P.8, are common in first drafts and are a straightforward but avoidable cause of regulatory questions.

Building Module 3 Progressively

The most efficient approach to Module 3 preparation is to write it in parallel with the development programme rather than as a post-hoc assembly exercise. A regulatory team that is integrated with the development project can write each section as the underlying data is generated, identify data gaps early enough to address them before the submission deadline, and ensure consistency across sections because the same team holds the full data picture.

Ardena’s regulatory teams work alongside its development and manufacturing teams across all sites, enabling this progressive CMC dossier building approach. The regulatory scientists who advise on specification setting and process control are the same people reviewing the analytical data and manufacturing process descriptions as they are developed.

The Role of Amorphous Solid Dispersions (ASD) in Bioavailability Enhancement

The Solubility Problem in Modern Drug Development

Estimates from published literature suggest that more than 70% of new chemical entities in development pipelines have poor aqueous solubility. Many of these fall into BCS Class II (low solubility, high permeability) or Class IV (low solubility, low permeability) under the Biopharmaceutics Classification System. For these molecules, getting the drug into solution in the gastrointestinal tract fast enough and in sufficient concentration to achieve meaningful absorption is the central formulation challenge.

Amorphous solid dispersions (ASDs) address this challenge by converting the crystalline API into an amorphous form and dispersing it within a polymer matrix. The result is a solid that dissolves faster and achieves higher apparent solubility in the gut than the crystalline starting material.

The Science Behind ASDs

Why Amorphous Forms Dissolve Faster

Crystalline solids require energy to break down the lattice structure before molecules can enter solution. Amorphous forms lack this ordered lattice, meaning the activation energy for dissolution is lower. An amorphous API can achieve supersaturation concentrations in the gut, providing a higher driving force for absorption, provided the supersaturated state is maintained long enough for absorption to occur.

The Role of the Polymer

Without stabilisation, amorphous APIs will tend to recrystallise over time, losing their bioavailability advantage. The polymer matrix in an ASD serves two functions: it provides a physical barrier that inhibits molecular mobility and recrystallisation, and it can interact with drug molecules through hydrogen bonding or other non-covalent interactions that further stabilise the amorphous state. Common polymers used in ASD manufacture include HPMC-AS, PVPVA, and Eudragit systems, each with different dissolution and stabilisation profiles.

Supersaturation and Precipitation Inhibition

In the gastrointestinal environment, a well-designed ASD generates a supersaturated drug solution. Maintaining that supersaturation requires the polymer to act as a precipitation inhibitor, preventing the drug from recrystallising in the gut fluid before it can be absorbed. The selection of polymer type and drug-to-polymer ratio is therefore critical not just for solid-state stability during storage but for the in vivo performance of the dosage form.

ASD Technology Platforms

Technology	Principle	Best Suited For	Key Consideration
Spray drying	API and polymer dissolved in solvent, spray atomised and dried	High-throughput screening; scale-up to commercial	Solvent selection and residual solvent control
Hot melt extrusion (HME)	API and polymer melt-blended under heat and shear	Thermally stable APIs; solvent-free processing	API must be thermally stable at processing temperatures
Coprecipitation	Anti-solvent addition causes simultaneous precipitation	Research scale; proof of concept	Scale-up can be challenging
Electrospinning	High-voltage electric field creates nanofibre matrices	Very low dose, highly potent APIs	Complex scale-up; niche application

Development Considerations for ASD Programmes

Drug Loading

Higher drug loading reduces the tablet size needed to deliver the target dose, which is important for patient acceptability. However, higher drug loading typically increases the risk of recrystallisation during storage. The optimal drug loading is a balance between these competing requirements, established through screening studies that evaluate physical stability at relevant storage conditions.

Stability Testing

An ASD formulation must demonstrate physical stability over its intended shelf life. Stability studies following ICH Q1 guidelines, combined with accelerated stress testing and XRPD monitoring to detect any crystalline conversion, form the basis of the stability data package. The glass transition temperature of the dispersion is a key parameter: a high Tg relative to storage temperature provides a greater kinetic barrier to recrystallisation.

Downstream Processing

The ASD intermediate, whether produced by spray drying or HME, needs to be converted into a final dosage form. The hygroscopicity, flowability, and compactibility of the ASD intermediate determine what downstream processing approach is feasible. Some ASDs require granulation before tabletting; others can be directly compressed.

Ardena’s ASD Capabilities

Ardena has dedicated ASD manufacturing capabilities at its Somerset, New Jersey facility and at the Pamplona (Idifarma) site in Spain. Both sites operate spray drying and hot melt extrusion platforms with clinical and commercial-scale capability. The development teams at these sites work in close coordination with Ardena’s solid state research group, ensuring that the polymer and drug loading decisions made in screening translate directly into the development programme.

For BCS Class II or IV molecules that have shown limited bioavailability in early animal studies, a conversation with Ardena’s formulation scientists about ASD feasibility is a worthwhile investment before committing to a clinical formulation strategy.

Co-Crystals vs. Salts: Which Is Right for Your API?

Two Strategies for the Same Problem

Poor aqueous solubility is one of the most common challenges in small molecule drug development. A molecule that does not dissolve adequately in the gastrointestinal fluid cannot be absorbed at a rate sufficient to achieve the intended therapeutic effect, regardless of how potent it is in a biochemical assay. Two of the most widely used solid form strategies for addressing this problem are pharmaceutical salts and co-crystals. Both involve creating a multicomponent solid that modifies the physical properties of the API, but they do so through different mechanisms, and each has a different regulatory footprint.

What Is a Pharmaceutical Salt?

A pharmaceutical salt is formed when an ionisable API reacts with a pharmaceutically acceptable acid or base to form an ionic compound. The positive and negative charges of the salt components are held together by electrostatic interactions. Salt formation is only possible when the API has an ionisable group with a suitable pKa, and where the difference in pKa between the API and the counterion is sufficient to drive proton transfer. As a general rule, a pKa difference of at least two units is required for reliable salt formation.

Salts are regulatory well-established. They are classified as the same active ingredient as the free form in most jurisdictions, which simplifies the regulatory pathway. The FDA has published guidance on the pharmaceutical salts framework, and the EMA’s ICH Q6A guideline addresses solid state characterisation requirements.

What Is a Pharmaceutical Co-Crystal?

A co-crystal is a multicomponent crystalline solid in which the API and a coformer are held together in the crystal lattice by non-covalent interactions, typically hydrogen bonds, rather than ionic bonds. Because no proton transfer occurs, co-crystal formation is not limited to ionisable molecules. This makes co-crystals particularly valuable for neutral or weakly ionisable APIs where salt formation is not feasible.

The regulatory status of co-crystals has evolved significantly over the past decade. The FDA’s 2018 guidance on co-crystals classifies them as drug products containing a drug substance, meaning they follow a standard NDA or ANDA regulatory pathway rather than being treated as new chemical entities. The EMA has taken a broadly similar position.

Salt vs. Co-Crystal: A Practical Comparison

Factor	Salt	Co-Crystal
Applicable molecules	Ionisable APIs (pKa difference > 2 units)	Ionisable and non-ionisable APIs
Interaction type	Ionic (electrostatic)	Non-ionic (hydrogen bonds, pi-pi stacking)
Regulatory classification	Same active ingredient as free form	Drug product containing drug substance (FDA)
IP potential	Well-established, many precedents	Growing body of co-crystal patents
Solubility improvement	Can be significant; dependent on counterion	Variable; coformer selection is critical
Physical stability	Generally robust if polymorph is stable	Can be hygroscopic; humidity sensitivity must be assessed
Coformer options	Pharmaceutically acceptable acids/bases	GRAS substances, excipients, or other APIs

Choosing the Right Approach for Your Molecule

Start with Ionisability

The first question is whether the API is ionisable. If it has a basic nitrogen or an acidic group with a pKa in the right range, salt screening is typically the first strategy to evaluate. If the molecule is neutral or weakly ionisable, co-crystal screening becomes the primary option alongside other solubility-enhancing technologies.

Consider the Stability Requirements

Some salts are hygroscopic or unstable at elevated humidity, which creates challenges during manufacturing and storage. Co-crystals can also show humidity sensitivity depending on the coformer. Understanding the stability profile of candidate forms under conditions relevant to your intended market, using ICH storage conditions as a minimum, is essential before committing to a development form.

Factor in the IP Landscape

If the free form and common salts of your API are already in the prior art, a novel co-crystal form with demonstrated physicochemical advantages may offer a patentable differentiation. A solid state research team with experience in the IP dimensions of form screening can help structure the work to generate data that supports a patent filing.

Ardena’s Approach to Salt and Co-Crystal Screening

Ardena’s solid state research team in Ghent conducts both salt and co-crystal screening as part of pre-formulation development programmes. The screening process uses a design-of-experiments approach to evaluate a broad range of counterions and coformers, with XRPD, DSC, and solution NMR used to characterise and confirm the nature of each candidate form.

Screening results are evaluated against the full development context, including target dose, intended manufacturing process, and the regulatory and IP strategy, so that the form recommendation reflects not just the best physical chemistry but the best outcome for the programme as a whole.